119 related articles for article (PubMed ID: 3878249)
1. Treatment of renal osteodystrophy in children with dihydrotachysterol and 24,25-dihydroxyvitamin D3.
van Diemen-Steenvoorde R; Donckerwolcke RA; Bosch R; Visser WJ; Raymakers JA; Duursma SA
Clin Nephrol; 1985 Dec; 24(6):292-9. PubMed ID: 3878249
[TBL] [Abstract][Full Text] [Related]
2. Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia.
Hodsman AB; Wong EG; Sherrard DJ; Brickman AS; Lee DB; Singer FR; Norman AW; Coburn JW
Am J Med; 1983 Mar; 74(3):407-14. PubMed ID: 6338716
[TBL] [Abstract][Full Text] [Related]
3. In vivo dihydrotachysterol2 metabolism in normal man: 1 alpha- and 1 beta-hydroxylation of 25-hydroxydihydrotachysterol2 and effects on plasma parathyroid hormone and 1 alpha,25-dihydroxyvitamin D3 concentrations.
Schroeder NJ; Trafford DJ; Cunningham J; Jones G; Makin HL
J Clin Endocrinol Metab; 1994 Jun; 78(6):1481-7. PubMed ID: 8200953
[TBL] [Abstract][Full Text] [Related]
4. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
[TBL] [Abstract][Full Text] [Related]
5. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
6. Serum dihydrotachysterol levels and biological action in normal man.
Taylor A; Bikle DD; Norman ME
J Clin Endocrinol Metab; 1988 Jul; 67(1):198-202. PubMed ID: 3379133
[TBL] [Abstract][Full Text] [Related]
7. 24,25-dihydroxyvitamin D3 in combination with 1,25-dihydroxyvitamin D3 ameliorates renal osteodystrophy in rats with chronic renal failure.
Gal-Moscovici A; Rubinger D; Popovtzer MM
Clin Nephrol; 2000 May; 53(5):362-71. PubMed ID: 11305809
[TBL] [Abstract][Full Text] [Related]
8. The effects of dihydrotachysterol therapy on the measurement of plasma 1,25-(OH)2-vitamin D in humans.
Gray RW; Adams ND; Caldas AE; Lemann J
J Lab Clin Med; 1979 Jun; 93(6):1031-4. PubMed ID: 438604
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy.
Muirhead N; Adami S; Sandler LM; Fraser RA; Catto GR; Edward N; O'Riordan JL
Q J Med; 1982; 51(204):427-44. PubMed ID: 6760236
[TBL] [Abstract][Full Text] [Related]
11. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW
Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832
[TBL] [Abstract][Full Text] [Related]
12. Proceedings: Bone demineralization in renal failure: a longitudinal study of the distal femur using photon absorptiometry.
Overton TR; Silverberg DS
AJR Am J Roentgenol; 1976 Jun; 126(6):1289-91. PubMed ID: 179410
[No Abstract] [Full Text] [Related]
13. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
16. [Hydroxylated metabolites of vitamin D. Therapeutic use of calcitriol and dihydrotachysterol].
Stĕpán J; Lachmanová J; Wilczek H; Straková M; Zichová M; Horn V; Tomásek R; Pacovský V
Cas Lek Cesk; 1985 Dec; 124(50):1550-6. PubMed ID: 3841297
[No Abstract] [Full Text] [Related]
17. Possible link between changes in plasma 24,25-dihydroxyvitamin D and healing of bone resorption in dialysis osteodystrophy.
Lambrey G; N'Guyen TM; Garabedian M; Sebert JL; de Fremont JF; Marie P; Caillens C; Gueris J; Meunier P; Balsan S; Fournier A
Metab Bone Dis Relat Res; 1982; 4(1):25-30. PubMed ID: 6981747
[TBL] [Abstract][Full Text] [Related]
18. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D.
Christiansen C; Christensen MS; Melsen F; Rødbro P; DeLuca HF
Clin Nephrol; 1981 Jan; 15(1):18-22. PubMed ID: 7214748
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D replacement therapy and renal function. Calcitriol v dihydrotachysterol.
Hymes LC; Warshaw BL
Am J Dis Child; 1984 Dec; 138(12):1125-8. PubMed ID: 6548870
[TBL] [Abstract][Full Text] [Related]
20. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D
Bone; 1992; 13(5):369-77. PubMed ID: 1419378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
